SVB Leerink Maintains Market Perform on bluebird bio, Raises Price Target to $10
SVB Leerink analyst Mani Foroohar maintains bluebird bio (NASDAQ:BLUE) with a Market Perform and raises the price target from $8 to $10.
Recap Of Wednesday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has approved Bluebird bio’s (NASDAQ:BLUE) lead asset ZYNTEGLO (betibeglogene autotemcel) to treat…
Bluebird’s Gene Therapy Scores US Approval For Genetic Blood Disorder, Probably The Most Expensive
The FDA has approved Bluebird bio Inc’s (NASDAQ:BLUE) Zynteglo (betibeglogene autotemcel), also known as beti-cel, a one-time gene therapy custom-designed for…
Bluebird Bio Announces U.S. Commercial Infrastructure To Enable Patient Access To ZYNTEGLO
Price of ZYNTEGLO reflects potentially curative clinical benefit through achievement of durable transfusion independence and normal or near normal total hemoglobin levels
Innovative outcomes-based contract offering
Bluebird Bio PR Announces FDA Approval Of ZYNTEGLO
ZYNTEGLO offers potentially curative benefit across ages and genotypes, through the achievement of durable transfusion independence and normal or near normal total hemoglobin levels
Management team to host conference
‘Bluebird wins U.S. approval for a gene therapy to treat patients with a rare blood disorder’ -STAT
https://www.statnews.com/2022/08/17/bluebird-wins-fda-approval-for-gene-therapy-for-beta-thalassemia/?utm_content=bufferba14a&utm_medium=social&utm_source=twitter&utm_campaign=twitter_organic
Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday
Gainers
AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method.
Analysts See Softened Timelines For CRISPR Therapeutics’ Sickle Cell Candidate In US
Barclays says that CRISPR Therapeutics AG’s (NASDAQ: CRSP) Q2 FY22 earnings release was largely incremental, highlighting the progress of multiple clinical programs, including the…
Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Verona Pharma plc (NASDAQ: VRNA) shares jumped 83.6% to $12.70 after the company announced ensifentrine met its primary endpoint and secondary endpoints in the Phase 3 ENHANCE-2 trial for COPD. The company also reported Q2 earnings results.